ACS Medicinal Chemistry Letters
Page 6 of 7
models of Parkinson's disease. Br. J. Pharmacol. 2012, 166, 1097-
1113.
15. Savolainen, M. H.; Richie, C. T.; Harvey, B. K.; Männistö, P. T.;
Maguire-Zeiss, K. A.; Myöhänen, T. T. The beneficial effect of a prolyl
oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and
autophagy in A30P transgenic mouse. Neurobiol. Dis. 2014, 68, 1-15.
16. Lawandi, J.; Gerber-Lemaire, S.; Juillerat-Jeanneret, L.;
Moitessier, N. Inhibitors of prolyl oligopeptidases for the therapy of
human diseases: Defining diseases and inhibitors. J. Med. Chem. 2010,
53, 3423-3438.
ACKNOWLEDGMENT
1
2
3
4
5
6
7
8
Dr Reinis Svarcbahs is acknowledged for assistance with PREP-
purification and Ms Nina Sipari for mass spectrometry. Reference
compound 7a (SUAM-1221), 7b and 14a (KYP-2047) were
obtained from our old compound library at the University of
Eastern Finland (earlier University of Kuopio).
ABBREVIATIONS
PREP, prolyl oligopeptidase; αSyn, alpha-synuclein; Aib, 2-
aminoisobutyric acid; Sar, sarcosine; MeAla, N-methyl-L-alanine;
βAla, beta-alanine; PCA, protein fragment complementation assay.
17. Jarho, E. M.; Venäläinen, J. I.; Poutiainen, S.; Leskinen, H.;
Vepsäläinen, J.; Christiaans, J. A. M.; Forsberg, M. M.; Männistö, P.
T.; Wallén, E. A. A. 2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
butanoyl)pyrrolidines
and
2(S)-(aroyl)-1-(4-
phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors.
Bioorg. Med. Chem. 2007, 15, 2024-2031.
18. Nakajima, T.; Ono, Y.; Kato, A.; Maeda, J.; Ohe, T. Y-29794 a
non-peptide prolyl endopeptidase inhibitor that can penetrate into the
brain. Neurosci. Lett. 1992, 141, 156-160.
19. Tarrago, T.; Kichik, N.; Segu, J.; Giralt, E. The natural product
berberine is a human prolyl oligopeptidase inhibitor. ChemMedChem.
2007, 2, 354-359.
REFERENCES
1. García-Horsman, J. A.; Männistö, P. T.; Venäläinen, J. I. On the
role of prolyl oligopeptidase in health and disease. Neuropeptides.
2007, 41, 1-24.
2. Myöhänen, T. T.; Venäläinen, J. I.; Tupala, E.; Garcia-Horsman,
J. A.; Miettinen, R.; Männistö, P. T. Distribution of immunoreactive
prolyl oligopeptidase in human and rat brain. Neurochem. Res. 2007,
32, 1365-1374.
3. Daly, D. J.; Maskrey, P.; Pennington, R. J. T. Characterization of
proline endopeptidase from skeletal muscle. Int. J. Biochem. 1985, 17,
521-524.
4. Goossens, F. H.; De Meester, I.; Vanhoof, G.; Scharpé, S.
Distribution of prolyl oligopeptidase in human peripheral tissues and
body fluids. Eur. J. Clin. Chem. Clin. Biochem. 1996, 34, 17-22.
5. Myöhänen, T. T.; Venäläinen, J. I.; García-Horsman, J. A.;
Piltonen, M.; Männistö, P. T. Distribution of prolyl oligopeptidase in
the mouse whole-body sections and peripheral tissues. Histochem. Cell
Biol. 2008, 130, 993-1003.
6. Myöhänen, T. T.; Pyykkö, E.; Männistö, P. T.; Carpen, O.
Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and
in Ovarian and Colorectal Tumors. J. Histochem. Cytochem. 2012, 60,
706-715.
7. Mantle, D.; Falkous, G.; Ishiura, S.; Blanchard, P. J.; Perry, E. K.
Comparison of proline endopeptidase activity in brain tissue from
normal cases and cases with Alzheimer's disease, Lewy body dementia,
Parkinson's disease and Huntington's disease. Clin. Chim. Acta. 1996,
249, 129-139.
8. Liu, J.; Kusinski, M.; Ilic, V.; Bignon, J.; Hajem, N.;
Komorowski, J.; Kuzdak, K.; Stepien, H.; Wdzieczak-Bakala, J.
Overexpression of the angiogenic tetrapeptide AcSDKP in human
malignant tumors. Anticancer Res. 2008, 28, 2813-2817.
9. Larrinaga, G.; Perez, I.; Blanco, L.; López, J. I.; Andrés, L.;
Etxezarraga, C.; Santaolalla, F.; Zabala, A.; Varona, A.; Irazusta, J.
Increased prolyl endopeptidase activity in human neoplasia. Regul.
Pept. 2010, 163, 102-106.
10. Brandt, I.; Gérard, M.; Sergeant, K.; Devreese, B.; Baekelandt,
V.; Augustyns, K.; Scharpé, S.; Engelborghs, Y.; Lambeir, A. Prolyl
oligopeptidase stimulates the aggregation of a-synuclein. Peptides.
2008, 29, 1472-1478.
11. Di Daniel, E.; Glover, C. P.; Grot, E.; Chan, M. K.; Sanderson,
T. H.; White, J. H.; Ellis, C. L.; Gallagher, K. T.; Uney, J.; Thomas, J.;
Maycox, P. R.; Mudge, A. W. Prolyl oligopeptidase binds to GAP-43
and functions without its peptidase activity. Mol. Cell. Neurosci. 2009,
41, 373-382.
12. Savolainen, M. H.; Yan, X.; Myöhänen, T. T.; Huttunen, H. J.
Prolyl oligopeptidase enhances a-Synuclein dimerization via direct
protein-protein interaction. J. Biol. Chem. 2015, 290, 5117-5126.
13. Tsirigotaki, A.; Van Elzen, R.; Van Der Veken, P.; Lambeir, A.
; Economou, A. Dynamics and ligand-induced conformational changes
in human prolyl oligopeptidase analyzed by hydrogen/deuterium
exchange mass spectrometry. Sci. Rep. 2017, 7.
14. Myöhänen, T. T.; Hannula, M. J.; Van Elzen, R.; Gerard, M.;
Van Der Veken, P.; García-Horsman, J. A.; Baekelandt, V.; Männistö,
P. T.; Lambeir, A. M. A prolyl oligopeptidase inhibitor, KYP-2047,
reduces a-synuclein protein levels and aggregates in cellular and animal
20. Kumar, R.; Bavi, R.; Jo, M. G.; Arulalapperumal, V.; Baek, A.;
Rampogu, S.; Kim, M. O.; Lee, K. W. New compounds identified
through in silico approaches reduce the a-synuclein expression by
inhibiting prolyl oligopeptidase in vitro. Sci. Rep. 2017, 7.
21. Tarragó, T.; Kichik, N.; Claasen, B.; Prades, R.; Teixidó, M.;
Giralt, E. Baicalin, a prodrug able to reach the CNS, is a prolyl
oligopeptidase inhibitor. Bioorg. Med. Chem. 2008, 16, 7516-7524.
22. Tsutsumi S.; Okonogi T.; Shibahara S.; Ohuchi S.; Hatsushiba
E.; Patchett A. A.; Christensen B. G. Synthesis and structure-activity
relationships of peptidyl alpha-keto heterocycles as novel inhibitors of
prolyl endopeptidase. J. Med. Chem. 1994, 37, 3492-3502
23. Bal G.; Van der Veken P.; Antonov D.; Lambeir A.-M.; Grellier
P.; Croft S.L.; Augustyns K.; Haemers A. Prolylisoxazoles: potent
inhibitors of prolyloligopeptidase with antitrypanosomal activity.
Bioorg. Med. Chem. Lett. 2003, 13, 2875-2878.
24. Saito, M.; Hashimoto, M.; Kawaguchi, N.; Shibata, H.; Fukami,
H.; Tanaka, T.; Higuchi, N. Synthesis and inhibitory activity of acyl-
peptidyl-pyrrolidine derivatives toward post-proline cleaving enzyme;
a study of subsite specificity. J. Enzyme Inhib. Med. Chem. 1991, 5, 51-
75.
25. Jarho, E. M.; Venäläinen, J. I.; Huuskonen, J.; Christiaans, J. A.
M.; Garcia-Horsman, J. A.; Forsberg, M. M.; Järvinen, T.; Gynther, J.;
Männistö, P. T.; Wallén, E. A. A. A cyclopent-2-enecarbonyl group
mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J.
Med. Chem. 2004, 47, 5605-5607.
26. Kaszuba, K.; Róg, T.; Danne, R.; Canning, P.; Fülöp, V.; Juhász,
T.; Szeltner, Z.; St. Pierre, J. -.; García-Horsman, A.; Männistö, P. T.;
Karttunen, M.; Hokkanen, J.; Bunker, A. Molecular dynamics,
crystallography and mutagenesis studies on the substrate gating
mechanism of prolyl oligopeptidase. Biochimie. 2012, 94, 1398-1411.
27. Van Der Veken, P.; Fülöp, V.; Rea, D.; Gerard, M.; Van Elzen,
R.; Joossens, J.; Cheng, J. D.; Baekelandt, V.; De Meester, I.; Lambeir,
A.; Augustyns, K. P2-substituted N-acylprolylpyrrolidine inhibitors of
prolyl oligopeptidase: Biochemical evaluation, binding mode
determination, and assessment in a cellular model of synucleinopathy.
J. Med. Chem. 2012, 55, 9856-9867.
28. Venäläinen, J. I.; Garcia-Horsman, J. A.; Forsberg, M. M.;
Jalkanen, A.; Wallén, E. A. A.; Jarho, E. M.; Christiaans, J. A. M.;
Gynther, J.; Männistö, P. T. Binding kinetics and duration of in vivo
action of novel prolyl oligopeptidase inhibitors. Biochem. Pharmacol.
2006, 71, 683-692.
29. Venäläinen, J. I.; Juvonen, R. O.; Forsberg, M. M.; Garcia-
Horsman, A.; Poso, A.; Wallen, E. A. A.; Gynther, J.; Männistö, P. T.
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl
oligopeptidase and its tight binding inhibition by JTP-4819. Biochem.
Pharmacol. 2002, 64, 463-471.
ACS Paragon Plus Environment